Top Key Companies for Preventive Vaccines Market: GlaxoSmithKline plc, Emergent BioSolutions Inc., Daiichi Sankyo Co. Ltd, Bavarian Nordic A/S, Merck & Co., Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Moderna Inc., China National Biotec Group Company Ltd., Novavax, Inc., CSL Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi SA.
Global Preventive Vaccines Market Research Report: 2026-2035 Outlook with Market Insights, Industry and Competitive Analysis Included. Remarkable growth trajectory projected.
Global Preventive Vaccines Market Overview And Scope:
The Global Preventive Vaccines Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Preventive Vaccines utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Preventive Vaccines Market Segmentation
By Type, Preventive Vaccines market has been segmented into:
Live/Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Conjugate Vaccines
Recombinant Vector Vaccines
Other Vaccines
By Application, Preventive Vaccines market has been segmented into:
Pneumococcal Disease
Poliovirus
Hepatitis
Influenza
Measles
Mumps
and Rubella (MMR)
Varicella
Human Papilloma Virus
COVID-19
Other Diseases
Regional Analysis of Preventive Vaccines Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Preventive Vaccines Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Preventive Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Preventive Vaccines market.
Top Key Companies Covered in Preventive Vaccines market are:
GlaxoSmithKline plc
Emergent BioSolutions Inc.
Daiichi Sankyo Co. Ltd
Bavarian Nordic A/S
Merck & Co.
Pfizer Inc.
Johnson & Johnson
AstraZeneca plc
Moderna Inc.
China National Biotec Group Company Ltd.
Novavax
Inc.
CSL Ltd.
Takeda Pharmaceutical Co. Ltd.
Sanofi SA
Key Questions answered in the Preventive Vaccines Market Report:
1. What is the expected Preventive Vaccines Market size during the forecast period, 2026-2035?
2. Which region is the largest market for the Preventive Vaccines Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Preventive Vaccines Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Preventive Vaccines Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Preventive Vaccines companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Preventive Vaccines Markets?
7. How is the funding and investment landscape in the Preventive Vaccines Market?
8. Which are the leading consortiums and associations in the Preventive Vaccines Market, and what is their role in the market?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Preventive Vaccines Market by Type
5.1 Preventive Vaccines Market Overview Snapshot and Growth Engine
5.2 Preventive Vaccines Market Overview
5.3 Live/Attenuated Vaccines
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Live/Attenuated Vaccines: Geographic Segmentation
5.4 Inactivated Vaccines
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Inactivated Vaccines: Geographic Segmentation
5.5 Subunit Vaccines
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Subunit Vaccines: Geographic Segmentation
5.6 Toxoid Vaccines
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Toxoid Vaccines: Geographic Segmentation
5.7 Conjugate Vaccines
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2026-2035F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Conjugate Vaccines: Geographic Segmentation
5.8 Recombinant Vector Vaccines
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2026-2035F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Recombinant Vector Vaccines: Geographic Segmentation
5.9 Other Vaccines
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size (2026-2035F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Other Vaccines: Geographic Segmentation
Chapter 6: Preventive Vaccines Market by Application
6.1 Preventive Vaccines Market Overview Snapshot and Growth Engine
6.2 Preventive Vaccines Market Overview
6.3 Pneumococcal Disease
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Pneumococcal Disease: Geographic Segmentation
6.4 Poliovirus
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Poliovirus: Geographic Segmentation
6.5 Hepatitis
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Hepatitis: Geographic Segmentation
6.6 Influenza
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2026-2035F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Influenza: Geographic Segmentation
6.7 Measles
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2026-2035F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Measles: Geographic Segmentation
6.8 Mumps
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2026-2035F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Mumps: Geographic Segmentation
6.9 and Rubella (MMR)
6.9.1 Introduction and Market Overview
6.9.2 Historic and Forecasted Market Size (2026-2035F)
6.9.3 Key Market Trends, Growth Factors and Opportunities
6.9.4 and Rubella (MMR): Geographic Segmentation
6.10 Varicella
6.10.1 Introduction and Market Overview
6.10.2 Historic and Forecasted Market Size (2026-2035F)
6.10.3 Key Market Trends, Growth Factors and Opportunities
6.10.4 Varicella: Geographic Segmentation
6.11 Human Papilloma Virus
6.11.1 Introduction and Market Overview
6.11.2 Historic and Forecasted Market Size (2026-2035F)
6.11.3 Key Market Trends, Growth Factors and Opportunities
6.11.4 Human Papilloma Virus: Geographic Segmentation
6.12 COVID-19
6.12.1 Introduction and Market Overview
6.12.2 Historic and Forecasted Market Size (2026-2035F)
6.12.3 Key Market Trends, Growth Factors and Opportunities
6.12.4 COVID-19: Geographic Segmentation
6.13 Other Diseases
6.13.1 Introduction and Market Overview
6.13.2 Historic and Forecasted Market Size (2026-2035F)
6.13.3 Key Market Trends, Growth Factors and Opportunities
6.13.4 Other Diseases: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Preventive Vaccines Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Preventive Vaccines Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Preventive Vaccines Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 GLAXOSMITHKLINE PLC
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 EMERGENT BIOSOLUTIONS INC.
7.4 DAIICHI SANKYO CO. LTD
7.5 BAVARIAN NORDIC A/S
7.6 MERCK & CO.
7.7 PFIZER INC.
7.8 JOHNSON & JOHNSON
7.9 ASTRAZENECA PLC
7.10 MODERNA INC.
7.11 CHINA NATIONAL BIOTEC GROUP COMPANY LTD.
7.12 NOVAVAX
7.13 INC.
7.14 CSL LTD.
7.15 TAKEDA PHARMACEUTICAL CO. LTD.
7.16 SANOFI SA
Chapter 8: Global Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Live/Attenuated Vaccines
8.2.2 Inactivated Vaccines
8.2.3 Subunit Vaccines
8.2.4 Toxoid Vaccines
8.2.5 Conjugate Vaccines
8.2.6 Recombinant Vector Vaccines
8.2.7 Other Vaccines
8.3 Historic and Forecasted Market Size By Application
8.3.1 Pneumococcal Disease
8.3.2 Poliovirus
8.3.3 Hepatitis
8.3.4 Influenza
8.3.5 Measles
8.3.6 Mumps
8.3.7 and Rubella (MMR)
8.3.8 Varicella
8.3.9 Human Papilloma Virus
8.3.10 COVID-19
8.3.11 Other Diseases
Chapter 9: North America Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Live/Attenuated Vaccines
9.4.2 Inactivated Vaccines
9.4.3 Subunit Vaccines
9.4.4 Toxoid Vaccines
9.4.5 Conjugate Vaccines
9.4.6 Recombinant Vector Vaccines
9.4.7 Other Vaccines
9.5 Historic and Forecasted Market Size By Application
9.5.1 Pneumococcal Disease
9.5.2 Poliovirus
9.5.3 Hepatitis
9.5.4 Influenza
9.5.5 Measles
9.5.6 Mumps
9.5.7 and Rubella (MMR)
9.5.8 Varicella
9.5.9 Human Papilloma Virus
9.5.10 COVID-19
9.5.11 Other Diseases
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Live/Attenuated Vaccines
10.4.2 Inactivated Vaccines
10.4.3 Subunit Vaccines
10.4.4 Toxoid Vaccines
10.4.5 Conjugate Vaccines
10.4.6 Recombinant Vector Vaccines
10.4.7 Other Vaccines
10.5 Historic and Forecasted Market Size By Application
10.5.1 Pneumococcal Disease
10.5.2 Poliovirus
10.5.3 Hepatitis
10.5.4 Influenza
10.5.5 Measles
10.5.6 Mumps
10.5.7 and Rubella (MMR)
10.5.8 Varicella
10.5.9 Human Papilloma Virus
10.5.10 COVID-19
10.5.11 Other Diseases
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Live/Attenuated Vaccines
11.4.2 Inactivated Vaccines
11.4.3 Subunit Vaccines
11.4.4 Toxoid Vaccines
11.4.5 Conjugate Vaccines
11.4.6 Recombinant Vector Vaccines
11.4.7 Other Vaccines
11.5 Historic and Forecasted Market Size By Application
11.5.1 Pneumococcal Disease
11.5.2 Poliovirus
11.5.3 Hepatitis
11.5.4 Influenza
11.5.5 Measles
11.5.6 Mumps
11.5.7 and Rubella (MMR)
11.5.8 Varicella
11.5.9 Human Papilloma Virus
11.5.10 COVID-19
11.5.11 Other Diseases
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Live/Attenuated Vaccines
12.4.2 Inactivated Vaccines
12.4.3 Subunit Vaccines
12.4.4 Toxoid Vaccines
12.4.5 Conjugate Vaccines
12.4.6 Recombinant Vector Vaccines
12.4.7 Other Vaccines
12.5 Historic and Forecasted Market Size By Application
12.5.1 Pneumococcal Disease
12.5.2 Poliovirus
12.5.3 Hepatitis
12.5.4 Influenza
12.5.5 Measles
12.5.6 Mumps
12.5.7 and Rubella (MMR)
12.5.8 Varicella
12.5.9 Human Papilloma Virus
12.5.10 COVID-19
12.5.11 Other Diseases
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Live/Attenuated Vaccines
13.4.2 Inactivated Vaccines
13.4.3 Subunit Vaccines
13.4.4 Toxoid Vaccines
13.4.5 Conjugate Vaccines
13.4.6 Recombinant Vector Vaccines
13.4.7 Other Vaccines
13.5 Historic and Forecasted Market Size By Application
13.5.1 Pneumococcal Disease
13.5.2 Poliovirus
13.5.3 Hepatitis
13.5.4 Influenza
13.5.5 Measles
13.5.6 Mumps
13.5.7 and Rubella (MMR)
13.5.8 Varicella
13.5.9 Human Papilloma Virus
13.5.10 COVID-19
13.5.11 Other Diseases
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Preventive Vaccines Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Live/Attenuated Vaccines
14.4.2 Inactivated Vaccines
14.4.3 Subunit Vaccines
14.4.4 Toxoid Vaccines
14.4.5 Conjugate Vaccines
14.4.6 Recombinant Vector Vaccines
14.4.7 Other Vaccines
14.5 Historic and Forecasted Market Size By Application
14.5.1 Pneumococcal Disease
14.5.2 Poliovirus
14.5.3 Hepatitis
14.5.4 Influenza
14.5.5 Measles
14.5.6 Mumps
14.5.7 and Rubella (MMR)
14.5.8 Varicella
14.5.9 Human Papilloma Virus
14.5.10 COVID-19
14.5.11 Other Diseases
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Preventive Vaccines Scope:
|
Report Data
|
Preventive Vaccines Market
|
|
Preventive Vaccines Market Size in 2025
|
USD XX million
|
|
Preventive Vaccines CAGR 2025 - 2032
|
XX%
|
|
Preventive Vaccines Base Year
|
2024
|
|
Preventive Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
GlaxoSmithKline plc, Emergent BioSolutions Inc., Daiichi Sankyo Co. Ltd, Bavarian Nordic A/S, Merck & Co., Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Moderna Inc., China National Biotec Group Company Ltd., Novavax, Inc., CSL Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi SA.
|
|
Key Segments
|
By Type
Live/Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Conjugate Vaccines
Recombinant Vector Vaccines
Other Vaccines
By Applications
Pneumococcal Disease
Poliovirus
Hepatitis
Influenza
Measles
Mumps
and Rubella (MMR)
Varicella
Human Papilloma Virus
COVID-19
Other Diseases
|
